Select a community
All Communities
Home > Patients

Showing 48 patients taking Natalizumab for Multiple Sclerosis (MS)

Status Natalizumab info Profile
kimberely4
Sex: F
Data Quality: 2 stars
MS: 6 yrs
Relapsing-Remitting
Sensation: Moderate
Overall: Mild
Cognition: moderate
Vision: none
Speech: none
Swallowing: moderate
Upper limb: moderate
Walking: moderate
kimberely4 kimberely4 Tysabri, 300 mg/15 mL every 4 weeks since Aug 28, 2009 optic neuritis onset: 12/02
Dx: 12/02
Type: Relapsing-Remitting
TYSABRI
Sex: F
Data Quality: 2 stars
MS: 25 yrs
Relapsing-Remitting
Sensation: Moderate
Overall: Mild
Cognition: moderate
Vision: none
Speech: moderate
Swallowing: none
Upper limb: moderate
Walking: moderate
TYSABRI Tysabri, 300 mg/15 mL every 4 weeks since Jun 15, 2009 difficulty walking onset: 07/84
Dx: 11/85
Type: Relapsing-Remitting
vjwebb59
Sex: F
Data Quality: 3 stars
MS: 9 yrs
Relapsing-Remitting
Sensation: Moderate
Overall: Moderate
Cognition: moderate
Vision: moderate
Speech: mild
Swallowing: moderate
Upper limb: moderate
Walking: moderate
vjwebb59 vjwebb59 Tysabri, 300 mg/15 mL every 4 weeks since Jan 15, 2008 sensory changes onset: 02/00
Dx: 04/00
Type: Relapsing-Remitting
mislissa1029
Sex: F
Data Quality: 3 stars
MS: 6 yrs
Relapsing-Remitting
Sensation: Severe
Overall: Moderate
Cognition: severe
Vision: moderate
Speech: mild
Swallowing: mild
Upper limb: moderate
Walking: moderate
mislissa1029 mislissa1029 Tysabri, 300 mg/15 mL every 4 weeks since Mar 09, 2009 sensory changes onset: 01/03
Dx: 05/03
Type: Relapsing-Remitting
caw692
Sex: F
Data Quality: 3 stars
MS: 16 yrs
Primary Progressive
Sensation: Moderate
Overall: Moderate
Cognition: moderate
Vision: moderate
Speech: moderate
Swallowing: moderate
Upper limb: moderate
Walking: moderate
caw692 caw692 Tysabri, 300 mg/15 mL every 4 weeks since Feb 01, 2008 optic neuritis onset: 01/93
Dx: 05/93
Type: Primary Progressive
Kia mara'
Sex: F
Data Quality: 1 star
MS: 6 yrs
Relapsing-Remitting
Sensation: Severe
Overall: Mild
Cognition: moderate
Vision: mild
Speech: none
Swallowing: mild
Upper limb: moderate
Walking: mild
Kia mara' Kia mara' Tysabri, 300 mg/15 mL every 4 weeks since Jul 10, 2009 difficulty walking onset: 08/03
Dx: 10/03
Type: Relapsing-Remitting
TwinkleCityMe
Sex: F
Data Quality: 1 star
MS: 24 yrs
I don't know
Sensation: Moderate
Overall: Mild
Cognition: moderate
Vision: none
Speech: none
Swallowing: none
Upper limb: mild
Walking: moderate
TwinkleCityMe Tysabri, 300 mg/15 mL every 4 weeks since Jul 01, 2005 sensory changes onset: 03/85
Dx: 07/98
Type: I don't know
cindy in arkansas
Sex: F
Data Quality: 1 star
MS: 11 yrs
Relapsing-Remitting
Sensation: Severe
Overall: Moderate
Cognition: severe
Vision: moderate
Speech: moderate
Swallowing: none
Upper limb: mild
Walking: moderate
cindy in arkansas cindy in arkansas Tysabri, 300 mg/15 mL monthly since Dec 01, 2007 sensory changes onset: 01/98
Dx: 06/00
Type: Relapsing-Remitting
HeidiK
Sex: F
Data Quality: 1 star
MS: 10 yrs
Relapsing-Remitting
Sensation: Mild
Overall: None
Cognition: mild
Vision: none
Speech: none
Swallowing: none
Upper limb: none
Walking: mild
HeidiK Tysabri, 300 mg/15 mL every 4 weeks since Aug 31, 2006 sensory changes onset: 06/99
Dx: 12/99
Type: Relapsing-Remitting
lexilew
Sex: F
Data Quality: 1 star
MS: 21 yrs
Secondary Progressive
Flare-up: Moderate
Sensation: Moderate
Overall: Moderate
Cognition: moderate
Vision: moderate
Speech: moderate
Swallowing: mild
Upper limb: moderate
Walking: moderate
lexilew Tysabri, 300 mg/15 mL monthly since Jan 05, 2009 optic neuritis onset: 01/88
Dx: 01/89
Type: Secondary Progressive
vibora329
Sex: M
Data Quality: 2 stars
MS: 4 yrs
Progressive Relapsing
Sensation: Severe
Overall: Mild
Cognition: moderate
Vision: mild
Speech: mild
Swallowing: mild
Upper limb: mild
Walking: moderate
vibora329 vibora329 Tysabri, 300 mg/15 mL monthly since Mar 29, 2008 difficulty thinking onset: 05/05
Dx: 08/05
Type: Progressive Relapsing

37 members have decided to share their profiles only with other members of the PatientsLikeMe Community. To see these profiles matching your search criteria, Join now!

ReportBack to Natalizumab report